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Abstract: Background: Vitamin D deficiency has been shown to be independently 
associated with increased risk of viral acute respiratory infection (ARI) in a number of 
observational studies, and meta-analysis of clinical trials of vitamin D supplementation for 
prevention of ARI has demonstrated protective effects. Several cellular studies have 
investigated the effects of vitamin D metabolites on immune responses to respiratory viruses, 
but syntheses of these reports are lacking. Scope: In this article, we review the literature 
reporting results of in vitro experiments investigating immunomodulatory actions of vitamin 
D metabolites in human respiratory epithelial cells infected with respiratory viruses. Key 
findings: Vitamin D metabolites do not consistently influence replication or clearance of 
rhinovirus, respiratory syncytial virus (RSV) or influenza A virus in human respiratory 
epithelial cell culture, although they do modulate expression and secretion of type 1 
interferon, chemokines including CXCL8 and CXCL10 and pro-inflammatory cytokines, 
such as TNF and IL-6. Future research: More studies are needed to clarify the effects of 
vitamin D metabolites on respiratory virus-induced expression of cell surface markers 
mediating viral entry and bacterial adhesion to respiratory epithelial cells. 
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1. Introduction 
Viral acute respiratory infections (ARI) are a leading cause of morbidity and mortality worldwide, 
and, as such, are a major global health problem. They are also responsible for a huge economic burden, 
precipitating considerable absence from work and school, and large numbers of visits to clinicians. 
The viral pathogens most commonly associated with acute respiratory infections are picornaviruses 
(including the species rhinovirus (RV) A, RVB, RVC and the enteroviruses A–D), orthomyxoviruses 
(influenza A, influenza B and influenza C), paramyxoviruses (including the parainfluenza viruses (PIV) 
1–4, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV)), coronaviruses, 
adenoviruses and human bocavirus (HBoV) [1–5]. The only routinely administered vaccine for a viral 
respiratory pathogen in the UK is against seasonal influenza: this is not 100% effective and may offer 
varying levels of protection against influenza infection in different seasons and different age groups [6]. 
The availability of effective antiviral drugs is also limited, with the effectiveness of approved influenza 
treatments, such as Oseltamivir (Tamiflu), debated [7–9], and no clinical treatments for common 
respiratory viruses such as rhinoviruses. New agents to prevent and treat viral respiratory infection are 
needed: the WHO initiative BRaVe (Battle against Respiratory Viruses) has recently been established to 
aid in the goal of developing new pharmacologic interventions to prevent and treat respiratory viruses [10]. 
Vitamin D is an immunomodulatory micronutrient [11,12]. As reviewed elsewhere [13], a number of 
observational studies have been carried out to determine the relationship between vitamin D status and 
acute respiratory viral infections, with the majority demonstrating independent associations between low 
vitamin D status and increased risk of acute viral respiratory infections. Clinical trials of vitamin D 
supplementation for the prevention of ARI have yielded heterogeneous results [14–27], with meta-analysis 
reporting moderate protective effects overall [28]. 
A number of in vitro studies have investigated the effects of vitamin D metabolites on host immune 
responses to respiratory viruses, but recent syntheses of this literature are lacking. In order to review 
these studies the PubMed database was searched using the terms “vitamin D” with the following 
respiratory viruses (rhinovirus, RSV, influenza, parainfluenza, human metapneumovirus, coronavirus, 
adenovirus, enterovirus and human bocavirus) to ensure a systematic review of the available literature. 
Inclusion criteria were studies which provided in vitro evidence as opposed to solely clinical studies, the 
availability of the full text, and for virus genera, such as enterovirus, which can infect multiple sites, the 
use of species or serotypes specifically associated with respiratory disease. 
2. The Host Immune Response to Viral Respiratory Infection 
2.1. Innate Immune Response 
When a respiratory virus is inhaled it first binds to non-specific receptors on the respiratory 
epithelium, usually glycolipids or glycoproteins such as intercellular adhesion molecule (ICAM)-1. 
Membrane fusion or endocytosis follows, thus internalizing the virus and enabling subsequent 
replication, transcription and translation of new viruses which can then be released to infect new cells. 
However, once a cell has been infected, pathogen-associated molecular patterns (PAMPs) on the virus 
can be recognised by various intracellular innate pathogen recognition receptors (PRRs) such as the  
toll-like receptors (TLRs), retinoic-acid-inducible gene-I (RIG-I)-like receptors (RLRs) and nucleotide 
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binding-oligomerisation domain (NOD)-like receptors (NLRs). Pulmonary epithelial cells have been 
shown to express all of the known human TLRs and RLRs which detect viruses, and ligands for these 
PRRs activate epithelial cells in order to initiate a rapid immune response against viral invasion [29]. In 
addition to direct infection of epithelial cells, intraepithelial dendritic cells (DCs), DCs residing just 
below the respiratory epithelium, and tissue-resident macrophages continually sample particles in the 
airway lumen and can internalize them by phagocytosis and macropinocytosis, thus activating PRRs and 
initiating an immune response [30,31]. 
The intracellular TLRs 3, 7, 8 and 9 are mainly located on the endoplasmic reticulum (ER) membrane 
before UNC93B1-dependent (an ER multi-transmembrane-domain-containing protein) trafficking to the 
endolysosome following viral infection [32,33]. These nucleic acid-sensing TLRs recognise single-stranded 
RNA (TLR 7/8) or unmethylated CpG double-stranded DNA motifs (TLR 9) of the viral genome, or the 
intermediary double-stranded RNA (TLR 3) produced during viral replication [34–37]. Additionally, 
TLR4 and TLR2 receptor complexes are able to traffic to the endolysosome and may play a role in viral 
recognition [37–41]. Viruses which avoid recognition by TLRs, can be recognised by RLRs which are 
present throughout the cytosol, with RIG-I important in the immune response to many RNA viruses [42], 
and melanoma differentiation-associated gene 5 (MDA5) crucial in the recognition of picornaviruses [43]. 
Additionally, the cytosolic NLR NOD2, whilst normally associated with the recognition of bacterial 
muramyl dipeptide, has also been demonstrated to be involved in the recognition of the ssRNA genome 
of RSV [44]. Despite differences in viral genomes, replication strategies, and the types of PRRs 
activated, common signalling pathways are utilized. Thus recognition of viral pathogens elicit conserved 
outcomes, with the interferon regulatory factor (IRF)-mediated production of type I IFNs a central feature, 
along with nuclear factor kappa B (NF-κB)- and mitogen-activated protein kinase (MAPK)- mediated 
regulation of various inflammatory cytokines [37,45] (Figure 1). 
Upon PAMP-PRR interaction and the activation of signalling transduction pathways, the type I IFNs 
(IFN-α and IFN-β) are some of the earliest cytokines to be produced. Their transcription and subsequent 
binding to the IFN receptor induces expression of a variety of interferon-stimulated genes (ISGs), with 
their products altering antiviral and immunomodulatory actions to limit and clear infection [45]. Features 
of the induced anti-viral state include resistance to viral replication in all cells, induction of apoptotic 
cell death in infected cells, increased major histocompatibility complex (MHC) class I expression to 
enhance antigen presentation, activation of dendritic cells (DCs) and macrophages, and stimulation of 
natural killer (NK) cells to enhance their cytolytic activity [46]. The inflammatory cytokines TNF-α, IL-1β, 
IL-6 and IL-12 are also produced at an early stage of the innate immune response. These cytokines 
promote leukocyte extravasation by increasing endothelial expression of adhesion molecules, such as 
ICAM-1 and VCAM-1, increase vascular permeability, induce synthesis of acute phase proteins, and 
contribute to recruitment and activation of cells of the adaptive immune response. Additionally, IL-1β 
and TNF-α amplify the inflammatory response by triggering further NF-κB and MAPK activation [47]. 
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Figure 1. Pathogen recognition receptor signalling following viral infection. Ligand-induced 
dimerisation occurs following PAMP recognition by endosomal TLRs, which engages the 
Toll-IL-1 receptor (TIR) domains to initiate adaptor molecule recruitment and signal 
transduction. MYD88-dependent signalling results in the formation of an IRAK/TRAF6 
complex, which phosphorylates IRF7 to initiate transcription of type I IFN genes, and 
activates a TAK1/TAB2/3 complex to drive transcription of pro-inflammatory cytokine 
genes via activation of NF-κB, AP1 and CREB. TRIF-dependent signalling can also activate 
NF-κB, AP-1 and CREB via recruitment of TRAF6 and RIP1. Alternatively, TRAF3 is 
recruited, resulting in phosphorylation of IRF3 which translocates into the nucleus to induce 
expression of type I IFNs. RIG-I and MDA5 are also able to activate NF-κB and IRF3 via 
interaction with IPS-1 localized on the mitochondrial membrane through homophilic 
interactions between their CARD domains. Similarly, CARD domains of NOD2 also interact 
with IPS-1 resulting in transcription of type I IFN genes. The type I IFNs produced bind to 
their receptor, and, via STAT-mediating signalling, initiate gene transcription.  
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Innate PRR signalling also results in the production of the chemokines CXCL8, CXCL9, CXCL10 
and IL-15 which facilitate recruitment of neutrophils and NK cells, respectively [48,49]. While 
neutrophils and macrophages have well-defined roles in bacterial innate immunity, their function in 
antiviral immunity is less clear and is likely to be minimal, with inhibition of neutrophil recruitment to 
the lung demonstrated to have no effect on the course of influenza infection [50], and the antigen 
presenting capacity of macrophages in the respiratory tract demonstrated to be limited [51,52]. The 
antimicrobial peptide LL-37, which is produced by both neutrophils and macrophages, is traditionally 
viewed as a component of the immune response to bacteria. However, anti-viral activity of LL-37 has 
also been demonstrated against both enveloped and non-enveloped viruses, including influenza virus 
and RSV [53]. It has been shown to disrupt the membrane of influenza virus [54], modify cytokine 
production [54], enhance TLR3 signalling [55], and have direct effects on RSV viral particles and 
infected epithelial cells, with diminished spread of infection and inhibited production of new virus 
particles [56]. Macrophages may also have a critical role in the resolution of inflammation and clearance 
of infection to prevent immunopathology. They are able to phagocytose infected cells and apoptotic 
cellular debris, which, if left in the lumen, can release chemokines, such as CXCL9 and CXCL10, 
resulting in recruitment of inflammatory cells and increased bystander tissue damage. In the absence of 
alveolar macrophages, or when macrophages have impaired function, airway occlusion can occur 
following RSV infection due to the accumulation of inflammatory cells, virus-infected cells, apoptotic 
debris and serum proteins, resulting in severe and potentially fatal bronchiolitis [57]. Similarly, 
following influenza infection in mice devoid of alveolar macrophages, pulmonary alveolar proteinosis 
(PAP) was demonstrated owing to the accumulation of surfactant material and a failure in efferocytosis, 
causing impaired gas exchange and fatal hypoxia [58]. Therefore, macrophages appear to have a vital 
role in the antiviral immune response, by producing antimicrobial peptides during the innate response, 
and phagocytosing dead cells and cellular debris to prevent immunopathology. 
2.2. Adaptive Immune Response 
PRR signalling facilitates the maturation and trafficking of dendritic cells, with the release of the 
chemokines CCL2 and CCL20, and increased expression of CCR7 [59,60]. Thus, around 72 h after 
infection, DCs with antigen-MHC complexes migrate through the afferent lymph vessels to secondary lymph 
nodes where they form interactions with naive CD4+ and CD8+ T lymphocytes. These T-lymphocytes are 
activated, proliferate, differentiate into effector T-cells and migrate via efferent lymph vessels into the 
circulation. Multiple chemokines, such as CCL3, CXCL9 and CXCL10, are expressed in the respiratory 
epithelium and result in changes in integrin affinity, allowing effector T-cells to bind to the endothelium 
and migrate into the infected tissue [37,61–64]. For efficient and effective viral clearance Th1 effector 
T-cells are required, which produce IL-2, TNF-α and IFN-γ to activate NK cells and induce generation 
of cytolytic molecules. CD8+ effector T-cells and NK cells can then induce apoptosis of infected cells 
via the release of cytolytic granules or by direct interaction between surface Fas receptor and Fas ligand 
(FasL) [37]. B-cells have also been demonstrated to play an important role in the immune response to 
highly pathogenic viral infections. Contact between CD4+ T-cells and naive B-cells in secondary 
lymphoid tissues results in their proliferation and antibody class-switching, with neutralizing virus-specific 
antibodies crucial for optimal viral clearance. Additionally, viral components expressed on infected cells 
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allow antibodies to bind, thus initiating antibody-dependent cell-mediated cytotoxicity (ADCC), 
whereby CD16 on NK cells recognises the Fc portion of antibodies bound to the surface and kills the 
target cell [37,65–67]. Complement is also increasingly being recognised as an important component of 
anti-viral immunity, as reviewed elsewhere [68]. The evolution of evasion mechanisms by viruses 
emphasises the importance of complement in anti-viral immunity, with, for example, the matrix protein 
M1 of influenza A able to bind to C1q to prevent interaction with antibodies on the surface of infected 
cells [68,69]. Therefore, combined, these effector mechanisms of the adaptive immune response rapidly 
clear the viral infection. 
3. Immunomodulatory Actions of Vitamin D Metabolites 
Vitamin D (cholecalciferol) is acquired from dietary sources, primarily oily fish, or from  
UV-mediated synthesis in the skin, before it is metabolised in the liver to form 25(OH)D3. This 
25(OH)D3 is the circulating form of vitamin D, with a half-life estimated to range from two weeks to  
two months [70–72], and its serum concentration is used to define vitamin D status. Further 
hydroxylation results in the synthesis of 1α,25(OH)2D3 and ligation of nuclear vitamin D receptors 
(VDRs), allowing subsequent binding to vitamin D responsive elements (VDREs) in promoter regions 
of specific genes, resulting in the repression or induction of gene transcription [11] (Figure 2). VDRs 
have also been shown to be located within the plasma membrane or its caveolae components [73–75], 
with ligation resulting in 1α,25(OH)2D3-mediated non-genomic rapid responses via the activation of 
second messenger systems, such as phospholipase C, protein kinase C and phosphatidylinositol-3′-
kinase (PI3K), thus initiating various intracellular effects, such as the opening of voltage-gated calcium 
channels and Ras/MAPK signal transduction [75,76]. The detection of VDR abundance throughout the 
immune system, the observation that VDR expression is regulated by immune signalling, and the 
detection of CYP27B1 expression by immune cells has directed vitamin D research into the area of 
immunology [77–81], with associations of low serum 25(OH)D3 levels seen with autoimmune diseases, 
cancer, cardiovascular disease and respiratory infections [82–85]. 
Significantly, a link has been made between TLR ligation and cytokine secretion, the expression of 
CYP27B1 and the expression of the VDR. In the absence of any influence by calcium homeostatic  
agents [86–88], and with a defective negative feedback mechanism [89,90], extra-renal  
1α-hydroxylation in cells such as monocytes and macrophages is regulated primarily by immune inputs. 
Therefore, this renders the immune system responsive to circulating levels of 25(OH)D and allows the 
sustained and potentially beneficial production of 1,25(OH)2D during an immune response [90]. 
Vitamin D metabolism in macrophages is linked to pathogen recognition, thus making it an integral 
part of the innate immune response [91]. Ligation of the TLR2/1 heterodimer in macrophages has been 
demonstrated to up-regulate CYP27B1, and the TLR8 ligands CL097 and ssRNA40 have also both been 
demonstrated to induce a dose-dependent increase in CYP27B1 mRNA and protein expression in 
macrophages [92]. Similarly, ligation of TLR4 by LPS up-regulated CYP27B1 expression in  
monocytes [93,94]. In dendritic cells, ligation of TLR4 by LPS or monophosphoryl lipid A (MPLA), 
and ligation of TLR3 by polyI:C induced expression of CYP27B1, altering DC migratory properties to 
allow their localisation into non-draining secondary lymphoid organs to present antigen peptides to CD4+  
T-cells [79,95–97]. Similarly, in human tracheobronchial epithelial (hTBE) cells, polyI:C stimulation 
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and addition of live RSV were demonstrated to increase CYP27B1 expression, enhance 25(OH)D 
conversion to 1,25(OH)2D, and amplify cathelicidin mRNA [98]. With the expression of TLRs in 
multiple cell types, and the ability to respond to a variety of pathogens, it is also possible that other TLRs 
or alternate PRRs may promote extra-renal expression of CYP27B1, allowing locally generated 
1,25(OH)2D to have even more extensive effects on the immune response. 
The exact mechanism by which TLR ligation enhances CYP27B1 production has not been fully 
defined, although the JAK-STAT, NF-κB and p38 MAPK pathways, and phosphorylation of the 
transcription factor C/EBPβ by p38 MAPK have been implicated [94]. Additionally, IL-15 has been 
demonstrated to act as an intermediary in promoting localized activity of CYP27B1 and synthesis of 
1,25(OH)2D. TLR 2/1 ligation by a triacylated lipopeptide of the M.tuberculosis 19 kDa antigen in 
human monocytes induced IL-15 secretion, which was required for the upregulation of CYP27B1 and 
the VDR, and subsequent downstream production of LL-37 [99]. Other cytokines, such as IL-13, IFNγ, 
IL-4, IL-1, IL-2 and TNF-α, have also been implicated as regulators of CYP27B1 expression and vitamin 
D metabolism [87,94,100–103]. The pathways involved in cytokine-regulated transcription of CYP27B1 are 
likely the same ones as utilized by TLR ligation-induced regulation, as described above [101]. 
Therefore, extra-renal 1,25(OH)2D synthesis has been shown to be regulated by TLR ligation and 
cytokine secretion, utilizing an intricate cross-talk between various signalling pathways. As such, in the 
presence of sufficient circulating levels of 25(OH)D, infection by respiratory viruses resulting in 
recognition by TLRs and cytokine production is able to increase levels of 1,25(OH)2D, hypothetically 
altering the immune response to better respond to these pathogens. 
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Figure 2. Metabolism of 1α,25(OH)2D3. Vitamin D3 is either obtained from dietary sources 
or UV synthesis, before two hydroxylations occur to produce the active metabolite 
1α,25(OH)2D3. TLR ligation can also increase levels of CYP27B1, resulting in enhanced  
1α-hydroxylation of 25(OH)D3. The 1α,25(OH)2D3 then binds to nuclear or membrane 
vitamin D receptors (VDRs). Nuclear VDR ligation results in heterodimerization with 
retinoid X receptor (RXR) and binding to vitamin D responsive elements (VDRE) in 
promoter regions of responsive genes. Components of the RNA polymerase II complex are 
then recruited for induction of gene transcription, or transcription is repressed. Membrane 
caveolae-associated VDR ligation results in the activation of second messenger systems, 
with one effect being the initiation of Ras/MAPK signal transduction. Nuclear MAPK 
modulates gene expression and engages in cross-talk with the VDR-RXR-VDRE complex. 
(Adapted from Slatopolsky et al. [104], and Parton and Simons [105]). 
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4. Effects of Vitamin D on the Innate Immune Response to Respiratory Pathogens 
Vitamin D has diverse and extensive effects on the immune system, due to the expression of the VDR 
and the enzyme CYP27B1 by most immune cells [11,77,81,106]. The most frequently demonstrated 
effect of vitamin D is that on LL-37, and, as such, its expression is commonly used to demonstrate 
increased CYP27B1 expression and 1,25(OH)2D activity. Cathelicidins are multifunctional antimicrobial 
peptides, and the sole form in humans is Human Cationic Antimicrobial Peptide of 18KDa (hCAP-18). 
From this precursor, the active form of LL-37 is cleaved by serine protease 3 in neutrophils [107]. While 
the method of cleavage has not been demonstrated in other cells types, LL-37 has been shown to be 
present in epithelial cells, monocytes, NK cells, B-cells and γδ T-cells [56,108], and can be secreted by 
respiratory epithelial cells onto the airway surface to form a first line of defence against invading 
pathogens [109]. It has many functions, as described elsewhere [110–115], such as direct facilitation of 
chemotaxis of immune cells and modification of DC differentiation, and, while traditionally viewed as 
a component of only the immune response to bacteria, has also been shown to act directly against  
viruses [53,54,56]. Numerous studies have demonstrated the role the 1,25(OH)2D-ligated VDR plays in 
binding to a VDRE in the promoter of the cathelicidin gene to enhance hCAP-18 production [116–119], 
thus suggesting a potential mechanism by which vitamin D may enhance innate immunity to  
respiratory infections. 
The proximal promoter region of DEFB4 gene also contains a VDRE, allowing 1,25(OH)2D to upregulate 
expression of β-defensin 2 [116]. This is another antimicrobial peptide, which, similarly to LL-37, is able to 
induce chemotaxis of immune cells and has been shown to inhibit RSV infection [120,121]. 
In addition to antimicrobial peptide induction, vitamin D has been demonstrated to modulate the innate 
immune system in a variety of other ways. Monocyte differentiation into macrophages is induced [122], 
with enhancement of the phagocytic and chemotactic capacity of macrophages [11,123], thus facilitating 
efferocytosis and preventing immunopathology. One of the signalling pathways regulated by vitamin D 
is the class III phosphatidylinositol 3-kinase complex (PI3KC3), with PI3K signalling associated with 
monocyte and macrophage generation of ROS and iNOS [124,125]. The oxidative burst has been 
demonstrated to have beneficial antiviral effects [126–129], although aberrant induction is associated 
with pathophysiology and tissue damage [130–132]. As such, vitamin D may have an important role in 
redox homeostasis, with evidence of both pro-oxidative induction of ROS and iNOS to boost the antiviral 
response [125,133], and antioxidative inhibition of iNOS and induction of ROS scavenging pathways to 
prevent immunopathology [134–136]. The ability of 1,25(OH)2D to induce monocyte autophagy has 
also been demonstrated. Autophagy acts as part of the immune system to remove damaged proteins and 
organelles, and is an important host defence mechanism against viral infections [137]. Vitamin D has 
been shown to induce autophagy by regulating multiple associated pathways, such as Bcl-2, mammalian 
target of rapamycin (mTOR), class III phosphatidylinositol 3-kinase complex, and cathelicidin 
production, thus potentially enhancing clearance of viruses and viral components [124,138,139]. 
Pattern recognition receptors have also been demonstrated to be regulated by vitamin D. Expression 
of TLR2 and TLR4 is inhibited in monocytes, resulting in impaired downstream signalling and 
hyporesponsiveness to PAMPS. With the observation that this effect is most prominent after 72 h, a 
negative feedback mechanism has been suggested, whereby excessive TLR activation is prevented at 
later stages of infection to dampen inflammation [11,140]. Conversely, CD14, an accessory protein to 
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TLR4 which has also been linked to TLR2 [141], was up-regulated by 1,25(OH)2D [140,142,143], but 
this effect was not sufficient to restore downstream TLR signalling [140]. Additionally, as opposed to 
its effects in monocytes, 1,25(OH)2D has been demonstrated to induce up-regulation of TLR2 in 
keratinocytes, allowing a mechanism by which vitamin D may prevent infection of wounds [144]. Finally, 
the intracellular receptor NOD2 is induced by 1,25(OH)2D in myeloid and epithelial cells, via two  
distal VDREs in the NOD2 gene. Addition of MDP (a lysosomal breakdown product of bacterial 
peptidoglycan [11]) to 1,25(OH)2D-induced NOD2 enhanced NF-κB signalling and subsequent  
β-defensin 2 expression [145]. 
5. Effects of Vitamin D on the Adaptive Immune Response to Respiratory Pathogens 
Vitamin D also modulates the adaptive immune response, and acts as a key intermediary between 
innate and adaptive immunity due to its influence on antigen presentation. 
Dendritic cells are the most potent antigen-presenting cells, and, as such, have a direct effect on 
lymphocyte activation and induction of the adaptive immune response. They reside in peripheral tissues 
in an immature state, sampling the environment and mediating antigen uptake, until a maturation signal 
induces migration to local lymph nodes and subsequent T-cell activation. Addition of 1,25(OH)2D has 
been demonstrated to inhibit DC differentiation, maturation and antigen presentation, with an associated 
decrease in markers such as CD1a, MHC class II, and the co-stimulatory molecules CD40, CD80 and 
CD86 [146–148], as well as abrogating the chemotactic response to CCL4 and CCL19 [149]. Already 
differentiated dendritic cells can also be redirected back towards a monocytic phenotype by the 
restoration of the monocytic marker CD14 [147,150]. 
The antigen-presenting and T-cell stimulatory capacity of monocytes and macrophages is also 
impaired by 1,25(OH)2D, with a decrease in MHC class II, CD40, CD80 and CD86. IL-12 production is 
suppressed in both activated DCs and macrophages, due to the 1,25(OH)2D-mediated down-regulation 
of NF-κB activation [151], while influence on the expression of TNF-α is dependent on the 
differentiation state of the cells, with a reduction observed following 1,25(OH)2D administration in  
LPS-stimulated monocytes and PBMCs [140,152]. 
The main function of DCs is to initiate T-cell responses, and thus the effect of 1,25(OH)2D on DCs 
has a major impact on T-cells. The decreased surface expression on DCs of co-stimulatory molecules 
and MHC class II results in a tolerogenic phenotype, with DC production of IL-12 (which is involved in 
driving Th1 differentiation) and IL-23 (which is involved in driving TH17 differentiation) inhibited by 
1,25(OH)2D [11,150]. Even when cultured with committed T-cells, these tolerogenic DCs caused 
hyporesponsiveness, decreased T-cell proliferation and reduced IFN-γ secretion [146,153]. IL-12, as 
well as stimulating the development of Th1 T-cells, also inhibits the development of Th2 cells, thus 
resulting in vitamin D shifting the balance of T-cells from a Th1 to a Th2 phenotype [154]. 
Concomitantly, DC production of IL-10 is increased. IL-10 is a cytokine with pleiotropic effects in 
immunoregulation, and levels in BAL fluid have been shown to be inversely correlated with 
severity/incidence of asthma [155,156]. This IL-10 production drives development of regulatory T-cells 
(Tregs), and these Tregs are able to secrete more IL-10 as well as the immunomodulatory cytokine TGF-β, 
while release of the Treg cytokine CCL22 is also increased [11]. Th17 cells and IL-17, have also been shown 
to be decreased, with calcitriol (1,25(OH)2D) reducing IL-17 production in a mouse colitis model and 
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impairing commitment to the Th17 lineage in mice with experimental autoimmune uveitis [157,158], 
although these effects may not translate to the human respiratory system. Th17 cells, by releasing IL-17, 
initiate an inflammatory response dominated by neutrophils. While high levels of IL-17 production are 
associated with chronic inflammation and severe immunopathology [159], deficient levels, as seen in 
Hyper-immunoglobulin E syndrome (HIES), result in recurrent fungal and bacterial infections [160]. 
Therefore, vitamin D may have a beneficial role in attenuating immunopathology caused by some 
infections, but be detrimental in other fungal and bacterial infections. 
1,25(OH)2D has also been demonstrated to have direct effects on T-cells, independent of DC activity. 
While the role of DCs in the induction of Tregs has been described, it has also been shown that 
1,25(OH)2D in combination with dexamethasone can induce a Treg population in the absence of APCs [161]. 
The proliferation and cytokine profiles of T-cells are also directly altered by 1,25(OH)2D. Production of 
IL-2, IFN-γ, TNF-α, IL-17 and IL-21 are all inhibited [157,162,163], with inhibition of IFN-γ further 
precluding macrophage activation, thus attenuating antigen presentation and the recruitment of other  
T-cells [164]. This direct inhibition of Th1-priming cytokines further skews T-cell differentiation 
towards a Th2 phenotype. 1,25(OH)2D is also able to upregulate the Th2-specific transcription factors 
GATA-3 and c-maf, resulting in increased production of IL-4, IL-5 and IL-10 [165]. B-cells are also 
affected by vitamin D, with modulation of T-cell responses altering the B-cell compartment, as well as 
having direct effects on B-cells themselves [11]. 1,25(OH)2D is able to inhibit proliferation, plasma-cell 
differentiation, immunoglobulin secretion and memory B-cell generation, while inducing B-cell 
apoptosis [80]. As such, vitamin D supplementation has been used in the treatment of B-cell-associated 
autoimmune diseases such as systemic lupus erythematous [166,167]. Finally, it has been suggested that 
vitamin D may affect other lymphocyte subsets, with VDR-KO mice presenting with fewer invariant 
natural killer (iNKT) cells [168], and CD8+ T-cells from MS patients secreting less IFN-γ and TNF-α 
and more IL-5 and TGF-β following 1,25(OH)2D treatment [169]. 
However, the mechanisms behind any potential beneficial role of vitamin D are unclear, with conflicting 
cellular studies on the effects of vitamin D on Th2 cells [170,171], with both enhancement [165] and 
inhibition [172] of IL-4 synthesis demonstrated. 1,25(OH)2D has also been shown to down-regulate  
DC-derived Ox40L, which is required for Th2 priming, thus, resulting in a reduced Th2 cytokine 
response in CD4+ T-cells from patients with allergic bronchopulmonary aspergillosis [173], thus 
contradicting evidence that vitamin D skews the T-cell phenotype towards a Th2 one. Additionally, the 
decrease in Th1 immunity which has been observed [11] would suggest a diminished immune response 
to pathogens, contrasting to the evidence suggesting an improved response to respiratory tract infections 
after vitamin D supplementation. Finally, while studies have demonstrated direct effects of 1,25(OH)2D 
administration on lymphocytes, others have shown that when using the inactive metabolite 25(OH)D, 
DCs are required to convert this precursor to the active 1,25(OH)2D to exert its immunomodulatory 
effects [174]. This indicates that administration of different vitamin D metabolites may result in a 
different response. Therefore, while vitamin D clearly acts as an immunomodulatory molecule with a 
wide range of effects demonstrated, the precise mechanisms are currently unclear, with the conflicting 
results reported also adding to the uncertainty of its actions. 
The main immunomodulatory effects of vitamin D are summarised in Figure 3. 
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Figure 3. The immunomodulatory actions of 1,25(OH)2D. 1,25(OH)2D has diverse and 
extensive effects on the immune compartment. The innate immune response is affected, with 
monocytes producing more LL-37 and β-defensin, with increased NOD2 expression and 
autophagy, while also producing diminished amounts of inflammatory cytokines, with 
decreased expression of TLR2 and TLR4. Differentiation into macrophages is increased, 
with macrophages having an increased capacity for phagocytosis and chemotaxis. However, 
their APC and T-cell stimulatory capacity is decreased. Monocyte and macrophage 
production of ROS and iNOS is able to both be induced and inhibited, thus regulating their 
balance. Differentiation into DCs is inhibited, with DCs expressing decreased levels of 
maturation surface markers. DC production of IL-12 and IL-23 is decreased, while mannose 
receptor expression and production of IL-10 and CCL22 are increased. When these 
tolerogenic DCs interact with T-cells, development of Tregs and Th2 cells is increased, with 
increased production of IL-10, TGF-β, IL-4 and IL-5. The development of Th1 and Th17 
cells is inhibited, with decreased production of IL-2, IFN-γ and TNF-α, and attenuation of 
macrophage activation. B-cells are also affected by 1,25(OH)2D, demonstrating decreased 
immunoglobulin production, proliferation and differentiation, but increased apoptosis. 
6. Effects of Vitamin D Metabolites on the Host Response to Respiratory Viruses 
While a number of in vitro studies have described the general effects of vitamin D metabolites on the 
function of immune cells and secretion of inflammatory molecules, as described above, experiments 
investigating the specific antiviral effects of vitamin D on each respiratory virus are limited. The 
available literature is summarised below, and presented in Figure 4. 
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Figure 4. The immunomodulatory actions of 1,25(OH)2D against respiratory viruses. 
Rhinovirus infection of epithelial cells results in increased production and secretion of  
pro-inflammatory cytokines and chemokines, with the secretion of CXCL8 and CXCL10 
further enhanced following treatment with 1,25(OH)2D. During RSV infection, IκBα 
expression is reduced, resulting in increased transcription of NF-κB-driven genes. STAT1 is 
also phosphorylated and able to translocate into the nucleus resulting in increased expression 
of IRF1 and IRF7. Pre-treatment with 1,25(OH)2D increases IκBα expression and decreases 
STAT1 phosphorylation, resulting in decreased production of CXCL10, IFN-β, MxA, 
ISG15, IRF1 and IRF7. Similarly, influenza A infection causes increased expression of  
pro-inflammatory cytokines and chemokines, with 1,25(OH)2D treatment causing decreased 
expression of TNF-α, IFN-β, ISG15, CXCL8, IL-6 and CCL5. Finally, 1,25(OH)2D is also 
able to increase LL-37 and HBD2 production, which have been shown to have antiviral 
effects against both RSV and influenza. 
  
 
Nutrients 2015, 7 4253 
 
6.1. Rhinovirus 
Rhinovirus is the most common aetiologic agent of the common cold, which in turn is the most 
frequent acute infection in the industrialised world, associated with two to three episodes per year in 
adults, and five to seven per year in children [175–177]. However, only one study has been carried out 
to determine the effect of vitamin D on rhinovirus infection [178]. Experiments were carried out in which 
primary human bronchial epithelial cells (hBECs) were treated with 25(OH)D or 1,25(OH)2D and 
subsequently infected with RV-16. Incubation with vitamin D metabolites had no effect on viral 
replication, and, whilst RV-16 infection induced hBEC secretion of CCL5, IL-6 and IL-29, incubation 
with vitamin D metabolites did not alter this effect. Treatment with vitamin D did, however, enhance 
secretion of CXCL8 and CXCL10, both in the presence and absence of rhinovirus infection. These 
molecules are pro-inflammatory chemokines, responsible for the recruitment of immune cells such as 
neutrophils, macrophages and T-cells to the site of infection, and could thus act as an effector mechanism 
as to how vitamin D alters the antiviral response to rhinovirus infection. 
6.2. RSV 
RSV is usually associated with illness in young children, with most infants having been infected by 
the age of three, causing a mild URI for the majority, but severe bronchiolitis in some [179,180]. It has 
also been associated with a higher risk of developing asthma in later life [181]. Vitamin D deficiency 
has been linked to RSV susceptibility, with low cord blood plasma concentrations of 25(OH)D related 
to RSV incidence in the first year of life [182], and single nucleotide polymorphisms (SNPs) in the VDR 
(rs10735810 and the Fokl SNP) and vitamin D binding protein (the GC1s variant) associated with a 
genetic predisposition to RSV bronchiolitis [183–186]. However, as with rhinovirus, in vitro work 
investigating the specific effects of vitamin D on the immune response to RSV is limited. 
In a study using primary human tracheobronchial epithelial (hTBE) cells treated with 1,25(OH)2D, 
expression of the NF-κB inhibitor IκBα was upregulated [187]. Cells infected with RSV for 24 h had 
decreased protein levels of IκBα, due to RSV-induced degradation, but in cells pre-treated with 
1,25(OH)2D prior to RSV infection IκBα levels were increased due to augmented mRNA transcription 
and protein synthesis. An increase in IκBα results in NF-κB remaining inactive in the cytoplasm, 
preventing its translocation into the nucleus and subsequent binding to DNA promoter regions. Thus, 
vitamin D inhibits RSV induction of NF-κB-driven IFN-β and CXCL10 secretion, as also demonstrated 
in this study. Additionally, interferon stimulated genes (ISGs) without functional NF-κB sites in their 
promoters were also measured, with 1,25(OH)2D treatment resulting in decreased levels of human 
myxovirus resistance protein 1 (MxA) and ISG15. This was demonstrated to be a consequence of the 
suppression of NF-κB-driven IFN-β production. Similarly, pre-treatment with 1,25(OH)2D before 
inoculation with RSV resulted in decreased levels of STAT1 protein and inhibition of STAT-1 
translocation to the nucleus, also as a consequence of suppression of NF-κB-driven IFN-β production. 
However, even though production of important components in the antiviral response to RSV infection 
(IFN-β, CXCL10, STAT1, MxA and ISG15) were reduced by treatment with 1,25(OH)2D, viral 
replication and viral load was not increased. Thus, via increasing IκBα levels, 1,25(OH)2D is able to 
dampen the inflammatory response to RSV infection whilst maintaining the antiviral state and without 
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having adverse effects on viral load, suggesting a potential role in reducing immunopathology. A similar 
study using alveolar A549 cells infected with RSV has also demonstrated that 1,25(OH)2D is able to 
decrease levels of phosphorylated STAT-1 (pSTAT-1) and increase IκBα protein levels, with subsequent 
diminished expression of interferon regulatory factor 1 (IRF1), IRF7, IFN-β and CXCL8 mRNA [188]. 
This study also used retroviral transduction to overexpress the common M4 VDR variant, or the M1 
FokI VDR variant, which has been associated with severe RSV bronchiolitis. No differences were 
observed between the two variants in viral replication, or the vitamin D-induced increase in IκBα and 
repression of NF-κB-regulated genes. However, in M1 FokI VDR-expressing cells, vitamin D was not 
able to repress expression of the STAT-1 regulated genes IRF1 and IRF7, due to decreased regulation 
of STAT-1 phosphorylation. Therefore, together these studies indicate that vitamin D is able to dampen 
NF-κB and STAT-1 mediated inflammation to reduce RSV immunopathology, with an impairment in 
the regulation of STAT-1 phosphorylation resulting in more severe disease. 
It has also been demonstrated that the antimicrobial peptides LL-37 and β-defensin 2 have anti-viral 
activity against RSV, blocking viral cellular entry, preventing virus-induced epithelial cell death, 
inhibiting production of new infectious particles and diminishing the spread of infection [56,121]. Since 
vitamin D has been demonstrated to be able to induce secretion of both of these molecules [116–118], this 
provides a potential mechanism by which vitamin D may exert antiviral effects against RSV infection. 
Finally, a number of studies have been carried out in calves, looking at the association between 
vitamin D and bovine RSV (BRSV). Naturally occurring BRSV infection in young ruminants has been 
demonstrated to mimic the pathogenesis and lesions observed in RSV infection of infants, thus providing 
a useful model for studying RSV infection. Conversely to the effects described above, whereby 
production of NF-κB-linked pro-inflammatory cytokines was inhibited, vitamin D treatment has been 
shown to elevate secretion of the pro-inflammatory cytokine IL-12p40 following BRSV infection [189]. 
No effect was observed on γδ T-cell cytokine production [190], or IFN-γ, CXCL8, TNF-α, IL-1β or IL-6 
secretion [189]. 
6.3. Influenza Virus 
The influenza virus is associated with seasonal epidemics, severe pandemics, pneumonia and 
secondary bacterial infections. As such, a simple and cost-effective prevention strategy is desirable, with 
clinical trial results showing promising effects of vitamin D supplementation in the prevention of 
seasonal influenza A infection in Japanese schoolchildren [17]. However, as with RSV and rhinovirus, 
in vitro work investigating the specific effects of vitamin D on the immune response to influenza viruses 
is lacking. 
In a study using alveolar A549 cells, the effect of pre- or post-treatment with 1,25(OH)2D on infection 
with influenza A H1N1 was assessed [191]. It was demonstrated that vitamin D had no effect on A549 
cell viability following infection with influenza virus, viral clearance or the anti-viral state. Whilst 
influenza infection increased the production of pro-inflammatory cytokines and chemokines, as with 
RSV infection [187,188], treatment with vitamin D either before or after influenza infection decreased 
gene expression of TNF-α, IFN-β, ISG15, CXCL8, IL-6 and RANTES (CCL5). Since an uncontrolled 
inflammatory response to influenza infection can cause complications such as pulmonary oedema, and 
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the cytokine storm has been associated with more severe disease and higher mortality [192]), this 
suppression of the hyper-inflammatory response may be beneficial in preventing immunopathology. 
The antimicrobial peptides LL-37 and human β-defensin 2 have also been shown to have anti-viral 
properties against influenza virus, reducing disease severity and viral replication, inhibiting infectivity, 
and demonstrating neutralising activity [54,193]. As described above, since vitamin D has been shown 
to induce production of these AMPs, this may be another mechanism by which vitamin D is able to exert 
antiviral effects on influenza virus infection. 
Finally, the majority of work into vitamin D and influenza infection has been investigating the 
potential use of vitamin D as an adjuvant in influenza vaccines. However, vitamin D has not been shown 
to be able to modulate the humoral response to inactivated influenza virus in this setting [194–198]. 
6.4. Other Respiratory Viruses 
In the case of other common viral causes of ARI in humans, no in vitro studies have been carried out 
to determine effects of vitamin D on the immune response to these pathogens. This is the case for human 
metapneumovirus, parainfluenza, adenovirus, coronaviruses, enterovirus and human bocavirus. 
7. Conclusions 
This review has identified a modest number of laboratory studies investigating immunomodulatory 
effects of vitamin D metabolites in respiratory epithelial cells infected with respiratory viruses. Despite 
clinical evidence that vitamin D supplementation may reduce susceptibility to such infections in vivo [28], 
in vitro studies performed to date have not shown that vitamin D metabolites inhibit viral replication in 
epithelial cells. However, all the studies reviewed demonstrated effects of vitamin D metabolites on 
expression and secretion of pro-inflammatory cytokines and chemokines. Interestingly, the effects of 
1,25(OH)2D on chemokine expression and secretion varied between pathogens; this finding 
complements those of clinical trials suggesting that vitamin D-inducible responses may be more effective 
against some pathogens than others [17]. More studies are needed to characterize the in vitro actions of 
vitamin D in viral respiratory infection (particularly to investigate why suppression of type 1 interferon 
responses is not associated with increased viral replication), and to clarify the effects of vitamin D 
metabolites on respiratory virus-induced expression of cell surface markers mediating viral entry and 
bacterial adhesion to respiratory epithelial cells. 
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